Vanderbilt Center For Neuroscience Drug Discovery
-
Vanderbilt receives $20 million from The William K. Warren Foundation to further treatments for brain disorders
Vanderbilt University has received $20 million from The William K. Warren Foundation, located in Tulsa, Oklahoma, to establish the Warren Center for Neuroscience Drug Discovery to support pharmaceutical breakthroughs. Read MoreMay 5, 2020
-
Study explores potential new class of antidepressants
Researchers at VUMC have taken a major step that could ultimately facilitate development of a new class of antidepressants which may relieve symptoms more rapidly and effectively and with fewer side effects than current medications. Read MoreNov 21, 2019
-
Yohn named Postdoc of the Year at annual symposium; Sappington named Mentor of the Year
Postdoctoral scholars Samantha Yohn and Anneke Sanders and ophthalmology professor Rebecca Sappington were honored by the Graduate School at the 13th Annual Vanderbilt Postdoctoral Association Symposium on April 9. Read MoreApr 22, 2019
-
Vanderbilt, Boehringer Ingelheim announce partnership to develop therapies for psychiatric disorders
Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors known to engage in the modulation of certain brain circuitries, which are altered in neuropsychiatric conditions such as schizophrenia. Read MoreJan 3, 2019
-
Lindsley named to National Academy of Inventors
Craig W. Lindsley, William K. Warren Jr. Professor of Medicine and co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been elected a fellow of the prestigious National Academy of Inventors. Read MoreDec 11, 2018
-
Ancora announces major funding awards to support Vanderbilt drug discovery research
Ancora Innovation, LLC, the new collaboration between Vanderbilt and Deerfield Management established earlier this year, has completed its inaugural proposal review process and announced two projects selected for funding. Read MoreNov 26, 2018
-
AAAS, chemistry society honor Lindsley’s research contributions
Craig Lindsley, PhD, co-director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), has been named a fellow of the Royal Society of Chemistry and elected chair-elect of the Section of Pharmaceutical Sciences of the American Association for the Advancement of Science (AAAS). Read MoreFeb 1, 2018
-
Investigators eye new target for treating movement disorders
Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported. Read MoreJan 18, 2018
-
Lindsley honored by Pharmaceutical Society of Japan
Craig Lindsley, PhD, the William K. Warren Jr. Professor of Medicine at Vanderbilt, is the 2018 recipient of the Sato Memorial International Award of the Pharmaceutical Society of Japan. Read MoreDec 7, 2017
-
Award honors Conn’s mental health research contributions
P. Jeffrey Conn, Ph.D., founding director of the Vanderbilt Center for Neuroscience Drug Discovery, has won a 2017 Research & Hope Award from the Pharmaceutical Research and Manufacturers of America (PhRMA) for outstanding research in the area of mental health. Read MoreOct 12, 2017
-
University of Kansas honors Lindsley’s pharmacology research
Craig Lindsley, Ph.D., co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been honored by the University of Kansas with the 2018 Edward E. Smissman Lectureship for his outstanding contributions to the fields of medicinal chemistry and molecular pharmacology. Read MoreSep 21, 2017
-
Drug discovery efforts may lead to new Rett syndrome treatments
Vanderbilt University research-ers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit. Read MoreAug 24, 2017
-
Investigational new drug for Alzheimer’s scheduled for first study in humans
Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center. Read MoreDec 27, 2016
-
Researchers eye potential schizophrenia ‘switch’
Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice. Read MoreSep 15, 2016
-
Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt
Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation. Read MoreAug 15, 2016
-
Putting schizophrenia to bed
A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation. Read MoreMar 21, 2016
-
Study reveals possible ‘dimmer switch’ drug for Rett syndrome
Researchers at Vanderbilt University Medical Center have relieved symptoms in a mouse model of Rett syndrome with a drug-like compound that works like the dimmer switch in an electrical circuit. Read MoreMar 3, 2016
-
Compound developed at VUMC may delay Huntington’s disease
A compound developed by researchers at Vanderbilt University can improve early symptoms and delay progression of Huntington’s disease in a mouse model of the neurodegenerative disorder. Read MoreOct 29, 2015
-
Grant enhances mental illness drug research efforts
Research at Vanderbilt University Medical Center aimed at developing potential new treatments for major depressive disorder, general anxiety disorder and post-traumatic stress disorder got a big boost this week from The William K. Warren Foundation of Tulsa, Oklahoma. Read MoreJul 16, 2015
-
Findings reveal new target in quest to ease schizophrenia
Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans. Read MoreMay 7, 2015